Latest Noven Pharmaceuticals Inc. Stories
New dose approved by FDA for the prevention of postmenopausal osteoporosis only; higher doses of Minivelle can also treat moderate to severe hot flashes due to menopause MIAMI and
MIAMI and NEW YORK, Oct.
Minivelle now approved for prevention of postmenopausal osteoporosis at all doses MIAMI and NEW YORK, Sept. 24, 2014 /PRNewswire/ -- Noven Pharmaceuticals, Inc.
MIAMI and NEW YORK, March 25, 2014 /PRNewswire/ -- Noven Pharmaceuticals, Inc. today announced the U.S. Patent and Trademark Office has issued U.S. Patent No.
Co-Promotion to Extend Physician Awareness of the First and Only FDA-Approved, Non-Hormonal Treatment for Moderate to Severe Menopausal Hot Flashes MIAMI and NEW YORK, Jan.
- Emitting flashes of light; glittering.